MAPK9 and cancer: Anti-cancer drugs such as doxorubicin, topotecan, carboplatin, cisplatin, etoposide, and paclitaxel have been observed to increase anti-GD2 mAbs activity by activation of stress-correlated pathways such as JNK/SAPK or PERK that make the tumor cells more sensitive to the antibody effect [24,25].